Multiple Myeloma Articles

Pomalidomide Effective in Multiple Myeloma With Renal Impairment
Pomalidomide in combination with low-dose dexamethasone induced an overall response rate of up to 39% in patients with relapsed/refractory multiple myeloma with renal impairment.
Pivotal Denosumab Data Published Highlighting Efficacy in Myeloma
Denosumab was noninferior to zoledronic acid in preventing skeletal-related event in patients with newly diagnosed multiple myeloma.
Expert Highlights Early Promise of Selinexor in Myeloma
Cristina Gasparetto, MD, discusses selinexor in combination with daratumumab and dexamethasone in patients with relapsed/refractory myeloma.
Higher Distress Scores Linked With Lower Survival in Myeloma
John Richter, MD, discusses the findings form the self-reported symptom and psychological survey in patients with multiple myeloma.
Pomalidomide Triplet Improves PFS in Relapsed/Refractory Myeloma
Adding pomalidomide to the combination of bortezomib and low-dose dexamethasone led to a significant improvement in progression-free survival in patients with relapsed/refractory myeloma with prior exposure to lenalidomide.
EMA Panel Backs Carfilzomib Label Update in Myeloma
The European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending a label variation for carfilzomib in patients with relapsed/refractory multiple myeloma.
Carfilzomib OS Benefit in Myeloma Highlighted in Published Findings
The combination of carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone extended overall survival for patients with relapsed or refractory multiple myeloma by nearly 8 months compared with lenalidomide and dexamethasone alone.
Wave of Therapies Being Developed in AL Amyloidosis Space
Sandy W. Wong, MD, discusses immunoglobulin light chain amyloidosissome and recent data that have shown excitement in this landscape.
CAR T-Cell Therapy an Emerging Explosion in Myeloma Paradigm
Nina Shah, MD, discusses immunotherapy and cellular treatments moving fast through the multiple myeloma pipeline, and the hope for CAR T-cell therapy to move up to earlier lines of treatment.
FDA Grants Priority Review to Frontline Daratumumab for Multiple Myeloma
The FDA has granted a priority review designation to daratumumab in combination with bortezomib, melphalan, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
Publication Bottom Border
Border Publication